menu

Quintiles Library

Show Filters
White Paper
Maximizing Quality and Efficiency of Go/No-Go Decisions in Early-phase Studies Due to the size and scope of clinical trials in this therapeutic area, traditional early oncology development has evidenced high start-up costs and long durations to advance to the Phase II setting. While the website ClinicalTrials.gov reveals that there are many products and programs in...
Explore here
White Paper
How is next generation sequencing (NGS) transforming oncology clinical development and treatments for cancer?  Read this recent whitepaper to learn how.  The overall goal in the era of emerging precision is to develop cancer medications that attack the right target, or targets, in the right disease, in the right patient, at the right dose to obtain the desired outcome....
Explore More
White Paper
Quintiles Outcome CER Briefing for NPC (National Pharmaceutical Council)
Explore here
White Paper
The number of people with dementia worldwide is forecast to rise to 115.4 million – or one in 85 people – by 2050. Improved techniques and technologies are being developed with the aim of early diagnosis of Alzheimer’s disease (AD), the most common form of dementia. Today, increasing numbers of AD clinical trials are mandating the use of biomarkers, in particular...
Explore here
White Paper
Managing the maintenance of marketed products on a global scale is an increasingly complex and costly endeavor. Even the largest companies are investigating ways to streamline operational infrastructure, yet they need people on the ground to deal with licensing, variations, renewals, label updates and other tasks that are required to maintain the regulatory status of...
Explore More
White Paper
The growing voice of stakeholders, from patients to payers, is changing the path of drug development. Nowhere is this trend more evident than in the oncology space. While evidence-based clinical medicine still stands as the prime driver, the additional driver that is emerging is overall treatment value. Value-based medicine is at the heart of a broadening debate on a host...
Explore here
White Paper
Given the growing knowledge of diseases, personalized medicine is becoming the standard of care. As a result, the demand for diagnostics has never been greater. Medical professionals, regulatory agencies and payers alike call for definitive tests that can improve treatment outcomes, reduce exposure to toxicity and help control costs.Earlier, in the first of this two-part...
Explore here
White Paper
This white paper discusses the significant burden of diabetes in pediatric populations, including the limited treatment options for pediatric patients with type 2 diabetes mellitus (T2DM). While type 1 diabetes mellitus (T1DM) has historically been the predominant diabetes disease in pediatric populations, T2DM now accounts for more than 10% of the incident cases of...
Explore here
White Paper
As the market for biosimilar products continues to grow, many biopharmaceutical companies trying to enter the space are struggling to overcome the unique challenges that developing such products presents. From navigating the complex global regulatory landscapes to ensuring optimal access, the development road for biosimilars is riddled with questions: How do we ensure...
Explore here
Brochure
FROM PIPELINE TO PORTFOLIO TO POPULATION HEALTH™ Creating a healthier world will require the industry’s best thinking and resources. It will also demand working together differently. Imagine a fully integrated approach that delivers biopharma and life sciences solutions through the healthcare continuum. At QuintilesIMS, we’re connecting insights with superior delivery for...
Read More
Brochure
Improve your probability of success:冊子 より健康な世界を創造するには、業界最高の発想と資源が必要です。 また、今まで考えられなかった協働も要求されます。 From pipeline to portfolio to population health™ (パイプラインからポートフォリオさらに人々の健康に至るまで)、バイオファーマとライフサイエンスのソリューションを実現する完全統合型アプローチを思い描いてください。 クインタイルズでは、より良い結果に向けて優れた情報提供力で見識を結集し、お客様の目標実現のために全力を尽くします。                       コンテンツは日本語です。
Read More
Press Release
RESEARCH TRIANGLE PARK, N.C. – December 17, 2014 – Quintiles CEO Tom Pike will present at the 2015 J.P. Morgan Healthcare Conference on Wednesday, January 14, 2015 in San Francisco at the Westin St. Francis Hotel. The Quintiles presentation will begin at 9:00 a.m. PST. Investors may access a live audio webcast of the presentation on the Quintiles’ Investor Relations...
Read More
Video
Oren Cohen, MD, Senior Vice President, Quintiles Early Clinical Development - discusses how Quintiles scientific and medical expertise can help customers get off to a better start, provide insights and high precision data to get to better go/no go decisions and to get to a more robust proof of concept.
Video
Graham Clarke, PhD, Senior Director and Head of Respiratory & Inflammation, Quintiles Early Clinical Development - discusses the importance’s of Respiratory research and how Quintiles has developed the BioSPIT initiative, a study to harmonize methodologies across dedicated centers for multi-center trials using induced sputum as a primary outcome measure for asthma and...
Presentation
This webinar focuses on benefit-risk management and evaluation and managing evolving regulatory safety standards. The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) are increasingly moving from a separate safety and effectiveness assessments model to combined benefit-risk assessments. Both the EMA and the FDA are making transparency a...
Explore More
Video
Dr Richard Adams, Clinical Oncologist, Cardiff University, Wales, explains the importance of engaging patients in biosimilars trials.
Press Release
SINGAPORE – December 9, 2014 – For the sixth time in eight years, Quintiles has been named Asia-Pacific Contract Research Organization of the Year by Frost & Sullivan, a leading business research and consulting firm. The award honors the CRO that scores the highest in Frost & Sullivan’s evaluation of several performance categories, including customer service;...
Read More
Brochure
The growing complexity of central nervous system (CNS) indications – from Alzheimer’s to schizophrenia to epilepsy – highlights the need for safer, more cost-effective treatment options. Biopharmaceutical companies developing CNS therapies face a number of challenges, including poor medication compliance, the need for intensive care delivery and multiple caregivers, the...
Read More
Press Release
RESEARCH TRIANGLE PARK, N.C.  – December 4, 2014 – Quintiles today announced that the company was awarded “Best Contract Research Organization” at the annual SCRIP Awards for the third year in-a-row. This is the company’s fourth award received in this category in the last five years. The SCRIP Awards acknowledge excellence in the biopharmaceutical industry, based on...
Read More
White Paper
With up to 70 percent of all trials experiencing enrollment delays, nearly half completing later than originally planned, and one-fifth of sites recruiting no patients, it’s clear that a new approach to study start-up is required. To reduce delays that negatively impact trial execution and future revenue, a more holistic, comprehensive method is emerging. Quintiles has...
Explore More